Akebia Therapeutics
AKBA
50 hedge funds and large institutions have $200M invested in Akebia Therapeutics in 2014 Q2 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
9,750% more capital invested
Capital invested by funds: $2.03M → $200M (+$198M)
1,567% more funds holding
Funds holding: 3 → 50 (+47)
1,567% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$36.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.5M |
| 3 |
HM
HealthCor Management
New York
|
+$21.7M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$1.22M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$449K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$361K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GGHC
51
Gilder Gagnon Howe & Co
New York
| – | -$1.22M | -62,380 | Closed |
|
|
LCM
52
Laurion Capital Management
New York
| – | -$449K | -22,975 | Closed |
|
|
53
Citadel Advisors
Miami,
Florida
| – | -$361K | -18,448 | Closed |
|
AKBA Hedge Fund Activity: Q2 2014 in Review
50 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2014, worth a combined $200M — up 9,750% from $2.03M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new AKBA positions and 3 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $36.5M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $1.22M sold.
- 50 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2014, up from 3 in Q1 2014.
- Funds reported $200M of Akebia Therapeutics stock for Q2 2014, up 9,750% quarter-over-quarter.
- 50 funds opened new Akebia Therapeutics positions in Q2 2014 and 3 closed out, a net change of +47 holders.
- The largest Akebia Therapeutics buyer in Q2 2014 was Novo Holdings A/S, an estimated $36.5M added.
- The largest Akebia Therapeutics seller in Q2 2014 was Gilder Gagnon Howe & Co, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2014.